Target

MSI-H

16 abstracts

Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).
Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Tracking the FDA precision oncology drug approval landscape in OncoKB.
Org: Memorial Sloan Kettering Cancer Center, Center for Molecular Oncology, Department of Pathology and Laboratory Medicine,
Abstract
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).
Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,
Abstract
Real-world rates of FDA-approved targeted therapy and immunotherapy prescriptions for metastatic colorectal cancer patients in the VA’s National Precision Oncology Program (NPOP).
Org: Center for Innovations in Quality Effectiveness and Safety, Houston, TX, VA Boston Healthcare System, Boston, MA, Baylor College of Medicine,
Abstract
Novel deep learning–based prognostic prediction model for colorectal cancer using hematoxylin and eosin–stained whole slide images.
Org: Biomy Inc., Tokyo, Japan, Akita University Graduate School of Medicine, Akita, Japan, Keio University School of Medicine,
Abstract
Deep learning-based approach to predict multiple genetic mutations in colorectal and lung cancer tissues using hematoxylin and eosin-stained whole-slide images.
Org: Biomy Inc., Akita University Graduate School of Medicine, Keio University School of Medicine,
Abstract
A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.
Org: Department of GI Oncology, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Peking University Cancer Hospital & Institute, Beijing Advanced Innovation Center for Big Data and Brain Computing, Beihang University,
Abstract
A novel patient-centric longitudinal data registry platform to generate insights into real-world cholangiocarcinoma (CCA) clinical practice.
Org: Invitae, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Mayo Clinic Arizona, Phoenix, AZ, Johns Hopkins University Bloomberg School of Public Health, Cholangiocarcinoma Foundation,
Abstract
Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing.
Org: Optum Labs, Eden Prairie, MN, Illumina, Inc., San Diego State University Department of Biology, San Diego, CA,
Abstract
Pattern of molecular testing among US veterans with gastrointestinal cancers: A single center experience.
Org: Veterans Affairs Medical Center, Oklahoma City, OK, Oklahoma City VA Health Care System,
Abstract
Comprehensive multi-omic testing from a single laboratory to provide information in ovarian cancer.
Org: Myriad Genetics, Inc., Myriad Genetic Laboratories, Inc.,
Abstract
Role of immune checkpoint inhibitors in PDL1-negative, low TMB, stable MSI metastatic solid tumours: Single centre study.
Org: HCG Cancer Centre Mumbai, Bangalore Institute of Oncology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Vydehi Institute of Medical Sciences & Research Centre,
Abstract
Assessing the real-world experience of treating gastric cancer in Armenia: A retrospective-study.
Org: Immune Oncology Research Institute, Pediatric Cancer and Blood Disorders Center of Armenia, Hematology Center After R.Yeolyan, Hematology center after prof. Yeolyan, Mikaelyan Institute of Surgery,